4-aminobenzoic acid has been researched along with Acute Myelogenous Leukemia in 9 studies
para-Aminobenzoates: Benzoic acids, salts, or esters that contain an amino group attached to carbon number 4 of the benzene ring structure.
4-aminobenzoate : An aromatic amino-acid anion that is the conjugate base of 4-aminobenzoic acid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with acute myeloid leukemia (AML) who achieve a morphologic complete remission still can have measurable residual disease (MRD) detected by multiparametric flow cytometry, molecular methods, or cytogenetics." | 2.61 | Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia. ( Estey, EH; Percival, MM, 2019) |
| " Physiologically-based pharmacokinetic models of idasanutlin and M4 have been established to simulate perpetrator and victim DDI scenarios and to evaluate whether further DDI studies in oncology patients are necessary." | 1.72 | Accelerating Clinical Development of Idasanutlin through a Physiologically Based Pharmacokinetic Modeling Risk Assessment for CYP450 Isoenzyme-Related Drug-Drug Interactions. ( Cleary, Y; Fowler, S; Parrott, N; Tuerck, D; Umehara, K, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 5 (55.56) | 2.80 |
| Authors | Studies |
|---|---|
| Umehara, K | 1 |
| Cleary, Y | 1 |
| Fowler, S | 1 |
| Parrott, N | 1 |
| Tuerck, D | 1 |
| Konopleva, MY | 1 |
| Röllig, C | 1 |
| Cavenagh, J | 1 |
| Deeren, D | 1 |
| Girshova, L | 1 |
| Krauter, J | 1 |
| Martinelli, G | 3 |
| Montesinos, P | 1 |
| Schäfer, JA | 1 |
| Ottmann, O | 1 |
| Petrini, M | 1 |
| Pigneux, A | 1 |
| Rambaldi, A | 1 |
| Recher, C | 1 |
| Rodriguez-Veiga, R | 1 |
| Taussig, D | 1 |
| Vey, N | 3 |
| Yoon, SS | 3 |
| Ott, M | 2 |
| Muehlbauer, S | 2 |
| Beckermann, BM | 1 |
| Catalani, O | 1 |
| Genevray, M | 1 |
| Mundt, K | 1 |
| Jamois, C | 1 |
| Fenaux, P | 1 |
| Wei, AH | 1 |
| Uy, GL | 1 |
| Assouline, S | 3 |
| Young, AM | 1 |
| Blotner, S | 3 |
| Higgins, B | 2 |
| Chen, LC | 3 |
| Yee, K | 3 |
| Corbali, MO | 1 |
| Eskazan, AE | 1 |
| Papayannidis, C | 1 |
| Dickinson, MJ | 2 |
| Kelly, KR | 2 |
| Kasner, M | 2 |
| Seiter, K | 2 |
| Drummond, MW | 1 |
| Lee, JH | 2 |
| Jukofsky, L | 2 |
| Pierceall, WE | 2 |
| Zhi, J | 1 |
| Simon, S | 1 |
| Nichols, G | 3 |
| Monnet, A | 1 |
| Pan, R | 1 |
| Ruvolo, V | 1 |
| Mu, H | 1 |
| Leverson, JD | 1 |
| Reed, JC | 1 |
| Konopleva, M | 1 |
| Andreeff, M | 1 |
| Percival, MM | 1 |
| Estey, EH | 1 |
| Reis, B | 1 |
| Chen, G | 1 |
| Zhong, H | 1 |
| So, WV | 1 |
| Drummond, M | 1 |
| Hashemyan, M | 1 |
| Theron, M | 1 |
| Rueger, R | 1 |
| Middleton, SA | 1 |
| Lehmann, C | 1 |
| Friess, T | 1 |
| Birzele, F | 1 |
| Kiialainen, A | 1 |
| Dangl, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center, Open-Label, First-in-Human, Phase I Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6839921, An MDM2 Antagonist, Following Intravenous Administration in Patients With Advanced Mali[NCT02098967] | Phase 1 | 68 participants (Actual) | Interventional | 2014-04-21 | Completed | ||
| A Multi-Center, Open-Label, Phase 1/1b Study of Escalating Doses of RO5503781 Administered Orally as 1) a Single Agent, 2) In Combination With Cytarabine, or 3) With Cytarabine and Anthracycline and 4) Assessing PK and Safety of New Optimized Formulation [NCT01773408] | Phase 1 | 122 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for 4-aminobenzoic acid and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antine | 2019 |
4 trials available for 4-aminobenzoic acid and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; | 2022 |
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Infusions, Intravenous; Leuke | 2020 |
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; | 2021 |
Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.
Topics: Blast Crisis; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Male; | 2016 |
4 other studies available for 4-aminobenzoic acid and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Accelerating Clinical Development of Idasanutlin through a Physiologically Based Pharmacokinetic Modeling Risk Assessment for CYP450 Isoenzyme-Related Drug-Drug Interactions.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Isoenzymes; Le | 2022 |
Idasanutlin as a new treatment option in improving the therapeutic odyssey of relapsed/refractory AML.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acut | 2020 |
Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heter | 2017 |
Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heter | 2016 |